The pharmaceutical industry hit bottom in public opinion, ranking last in Gallup’s list of 25 industries, according to a new annual poll.
The pharmaceutical industry hit bottom in public opinion, ranking last in Gallup’s list of 25 industries, according to a new annual poll.
The drug industry eclipsed the federal government for the lowest spot; in terms of its net-positive score; the government has been last or tied for last from 2011 through last year.
Americans are more than twice as likely to rate the pharmaceutical industry negatively (58%) as positively (27%), giving it a net-positive score of —31.
Net ratings for pharma have never been lower since Gallup’s poll about industries began in 2001. Over the past 19 years, few industries have been rated lower than the drug industry's current —31 net rating. Besides the federal government, other sectors in low regard have been the oil and gas, real estate, and automobile industries.
These data, which show the healthcare industry's negative ratings also exceed its positive ratings by double digits, are from Gallup's annual Work and Education poll, conducted from August 1 to 14.
The dead-last ranking comes amid continuing criticism of the drug industry. Democratic presidential candidates have turned cost issues into a rallying cry, and the industry’s role in the opioid crisis has been unveiled through massive lawsuits.
While there has been no shortage of hearings on Capitol Hill for the past year to address rising drug prices—whether it took the form of patients speaking out about rising insulin costs or executives talking about efforts to reform the use of patents—there has been little action, apart from actions taken by the Trump administration.
For instance, HHS has released 2 potential pathways for allowing the prospective importation of some drugs that were intended for foreign markets. But an effort to require drug pricing in television advertising has been blocked by the courts.
Gallup said the drug industry can hope to recover in the same way other industries have after particularly negative ratings. Real estate, for example, moved from being near the bottom of the list, with a net rating of —40 in 2008, to its current spot among the top 10-rated industries with a +30 net rating.
However, Gallup said a public image recovery is not likely until the drug pricing issue is resolved and the opioid crisis has passed.
Eye on Pharma: Golimumab Biosimilar Update; Korea Approves Denosumab; Xbrane, Intas Collaboration
December 10th 2024Alvotech and Advanz Pharma have submitted a European marketing application for their golimumab biosimilar to treat inflammatory diseases, while Celltrion secured Korean approval for denosumab biosimilars, and Intas Pharmaceuticals partnered with Xbrane Biopharma on a nivolumab biosimilar.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.